The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
p53 mutations in colorectal cancer- molecular pathogenesis and pharmacological reactivation
Open accessAbstract
Colorectal cancer (CRC) is one of the most common malignancies with high prevalence and low 5-year survival. CRC is a heterogeneous disease with a complex, genetic and biochemical background. It is now generally accepted that a few important intracellular signaling pathways, including Wnt/β-catenin signaling, Ras signaling, and p53 signaling are frequently dysregulated in CRC. Patients with mutant p53 gene are often resistant to current therapies, conferring poor prognosis. Tumor suppressor p53 protein is a transcription factor inducing cell cycle arrest, senescence, and apoptosis under cellular stress. Emerging evidence from laboratories and clinical trials shows that some small molecule inhibitors exert anti-cancer effect via reactivation and restoration of p53 function. In this review, we summarize the p53 function and characterize its mutations in CRC. The involvement of p53 mutations in pathogenesis of CRC and their clinical impacts will be highlighted. Moreover, we also describe the current achievements of using p53 modulators to reactivate this pathway in CRC, which may have great potential as novel anti-cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Erratum: PRIMA-1Met induces mitochondrial apoptosis through activation of caspase-2
Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., & Wiman, K. G. (2016) · Oncogene · doi:10.1038/onc.2016.210 · Cited by 54
RetractedPRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2
Shen, J., Vakifahmetoglu, H., Stridh, H., Zhivotovsky, B., & Wiman, K. G. (2008) · Oncogene · doi:10.1038/onc.2008.249 · Cited by 52
RetractedIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661
Cellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
A microRNA component of the p53 tumour suppressor network
He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z., Liang, Y., Xue, W., Zender, L., Magnus, J., Ridzon, D., et al. (2007) · Nature · doi:10.1038/nature05939 · Cited by 2,692
The first 30 years of p53: growing ever more complex.
Levine, A. J., & Oren, M. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2723 · Cited by 1,967
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
KILLER/DR5 is a DNA damage–inducible p53–regulated death receptor gene
Wu, G. S., Burns, T. F., McDonald, E. R., Jiang, W., Meng, R., Krantz, I. D., Kao, G., Gan, D.-D., Zhou, J.-Y., Muschel, R., et al. (1997) · Nature Genetics · doi:10.1038/ng1097-141 · Cited by 1,083
Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound
Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067
Cellular senescence and its effector programs
Salama, R., Sadaie, M., Hoare, M., & Narita, M. (2014) · Genes & Development · doi:10.1101/gad.235184.113 · Cited by 855
PML regulates p53 acetylation and premature senescence induced by oncogenic Ras
Pearson, M., Carbone, R., Sebastiani, C., Cioce, M., Fagioli, M., Saito, S., Higashimoto, Y., Appella, E., Minucci, S., Pandolfi, P. P., et al. (2000) · Nature · doi:10.1038/35018127 · Cited by 847
A role for both RB and p53 in the regulation of human cellular senescence*1
SHAY, J. (1991) · Experimental Cell Research · doi:10.1016/0014-4827(91)90453-2 · Cited by 757
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Regulation and function of the p53 tumor suppressor protein
Ryan, K. M., Phillips, A. C., & Vousden, K. H. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00216-7 · Cited by 721
Kortlever, R. M., Higgins, P. J., & Bernards, R. (2006) · Nature Cell Biology · doi:10.1038/ncb1448 · Cited by 637
miR-34 and SNAIL form a double-negative feedback loop to regulate epithelial-mesenchymal transitions
Siemens, H., Jackstadt, R., Hünten, S., Kaller, M., Menssen, A., Götz, U., & Hermeking, H. (2011) · Cell Cycle · doi:10.4161/cc.10.24.18552 · Cited by 609
PRIMA-1 reactivates mutant p53 by covalent binding to the core domain
Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592
Identification and Molecular Cloning of Two Novel Receptors for the Cytotoxic Ligand TRAIL
MacFarlane, M., Ahmad, M., Srinivasula, S. M., Fernandes-Alnemri, T., Cohen, G. M., & Alnemri, E. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.41.25417 · Cited by 557
PML is induced by oncogenic ras and promotes premature senescence
Ferbeyre, G., de Stanchina, E., Querido, E., Baptiste, N., Prives, C., & Lowe, S. W. (2000) · Genes & Development · doi:10.1101/gad.14.16.2015 · Cited by 536
MDM2 inhibitors for cancer therapy
Vassilev, L. T. (2007) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2006.11.002 · Cited by 532
Russo, A., Bazan, V., Iacopetta, B., Kerr, D., Soussi, T., & Gebbia, N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.00.471 · Cited by 416
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Translating p53 into the clinic
Cheok, C. F., Verma, C. S., Baselga, J., & Lane, D. P. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.174 · Cited by 381
TP53 mutation in colorectal cancer
Iacopetta, B. (2003) · Human Mutation · doi:10.1002/humu.10175 · Cited by 345
DNA microarrays identification of primary and secondary target genes regulated by p53
Kannan, K., Amariglio, N., Rechavi, G., Jakob-Hirsch, J., Kela, I., Kaminski, N., Getz, G., Domany, E., & Givol, D. (2001) · Oncogene · doi:10.1038/sj.onc.1204319 · Cited by 331
p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling
Kim, N. H., Kim, H. S., Kim, N.-G., Lee, I., Choi, H.-S., Li, X.-Y., Kang, S. E., Cha, S. Y., Ryu, J. K., Na, J. M., et al. (2011) · Science Signaling · doi:10.1126/scisignal.2001744 · Cited by 308
Self-citationNegative regulation of the tumor suppressor p53 gene by microRNAs
Kumar, M., Lu, Z., Takwi, A. A. L., Chen, W., Callander, N. S., Ramos, K. S., Young, K. H., & Li, Y. (2011) · Oncogene · doi:10.1038/onc.2010.457 · Cited by 284
Farnebo, M., Bykov, V. J. N., & Wiman, K. G. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.02.152 · Cited by 268
Colorectal cancer: genetics of development and metastasis
Takayama, T., Miyanishi, K., Hayashi, T., Sato, Y., & Niitsu, Y. (2006) · Journal of Gastroenterology · doi:10.1007/s00535-006-1801-6 · Cited by 265
PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis
Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252
Lane, D. P., Cheok, C. F., & Lain, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 246
Molecular Pathways: Targeting Mdm2 and Mdm4 in Cancer Therapy
Li, Q., & Lozano, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0053 · Cited by 190
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3
Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189
An overview of colorectal cancer survival rates and prognosis in Asia
Moghimi-Dehkordi, B. (2012) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v4.i4.71 · Cited by 186
Role of Ubiquitin Ligases and the Proteasome in Oncogenesis: Novel Targets for Anticancer Therapies
Micel, L. N., Tentler, J. J., Smith, P. G., & Eckhardt, G. S. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.0958 · Cited by 176
Baek, S. J. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh255 · Cited by 169
Tan, T. H., Wallis, J., & Levine, A. J. (1986) · Journal of Virology · doi:10.1128/jvi.59.3.574-583.1986 · Cited by 162
Le, M. T. N., Shyh-Chang, N., Khaw, S. L., Chin, L., Teh, C., Tay, J., O'Day, E., Korzh, V., Yang, H., Lal, A., et al. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002242 · Cited by 158
Current strategies to target p53 in cancer
Chen, F., Wang, W., & El-Deiry, W. S. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.04.031 · Cited by 158
Pharmacologic Activation of p53 by Small-Molecule MDM2 Antagonists
Shen, H., & Maki, C. G. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211795222603 · Cited by 148
Qian, Y., Zhang, J., Yan, B., & Chen, X. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m708624200 · Cited by 141
MicroRNA miR-125b is a prognostic marker in human colorectal cancer
Mori (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.969 · Cited by 139
The DNA Damage Signaling Pathway Connects Oncogenic Stress to Cellular Senescence
Mallette, F. A., & Ferbeyre, G. (2007) · Cell Cycle · doi:10.4161/cc.6.15.4516 · Cited by 125
Reyes‐Zurita, F. J., Pachón-Peña, G., Lizárraga, D., Rufino‐Palomares, E. E., Cascante, M., & Lupiáñez, J. A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-154 · Cited by 120
Iacopetta, B. M., Russo, A. D., Bazan, V., Dardanoni, G., Gebbia, V., Soussi, T., Kerr, D. J., Elsaleh, H., Soong, R., Kandioler, D., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl035 · Cited by 119
Zandi, R., Selivanova, G., Christensen, C. L., Gerds, T. A., Willumsen, B. M., & Poulsen, H. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3168 · Cited by 118
MiRNA-34 intrinsically links p53 tumor suppressor and Wnt signaling
Cha, Y. H., Kim, N. H., Park, C., Lee, I., Kim, H. S., & Yook, J. I. (2012) · Cell Cycle · doi:10.4161/cc.19618 · Cited by 115
Targeting p53 by small molecules in hematological malignancies
Saha, M. N., Qiu, L., & Chang, H. H. (2013) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-6-23 · Cited by 115
Kim, N. H., Cha, Y. H., Kang, S. E., Lee, Y. M., Lee, I., Cha, S. Y., Ryu, J. K., Na, J. M., Park, C., Yoon, H., et al. (2013) · Cell Cycle · doi:10.4161/cc.24739 · Cited by 111
Ray, R. M., Bhattacharya, S., & Johnson, L. R. (2010) · APOPTOSIS · doi:10.1007/s10495-010-0538-0 · Cited by 108
Inverse correlation between RER+ status and p53 mutation in colorectal cancer cell lines.
Cottu, P. H., Muzeau, F., Estreicher, A., Fléjou, J., Iggo, R. D., Thomas, G. D., & Hamelin, R. (1996) · PubMed · Cited by 104
Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer
Patel, S., & Player, M. R. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780802493366 · Cited by 103
Shangary, S., Ding, K., Qiu, S., Nikolovska-Coleska, Z., Bauer, J. A., Liu, M., Wang, G., Lu, Y., McEachern, D., Bernard, D., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0140 · Cited by 91
Hong, B., Prabhu, V. V., Zhang, S., van den Heuvel, A. P. J., Dicker, D. T., Kopelovich, L., & El‐Deiry, W. S. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0955 · Cited by 87
Hackl, C., Lang, S. A., Moser, C., Mori, A., Fichtner‐Feigl, S., Hellerbrand, C., Dietmeier, W., Schlitt, H. J., Geissler, E. K., & Stoeltzing, O. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-668 · Cited by 86
Key role of ATF3 in p53-dependent DR5 induction upon DNA damage of human colon cancer cells
Taketani, K., Kawauchi, J., Tanaka, M., Ishizaki, H., Tanaka, Y., Sakai, T., Miyoshi, J., Maehara, Y., & Kitajima, S. (2011) · Oncogene · doi:10.1038/onc.2011.397 · Cited by 83
Zhang, C., Gao, C., Kawauchi, J., Hashimoto, Y., Tsuchida, N., & Kitajima, S. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)02382-3 · Cited by 81
Translational approaches targeting the p53 pathway for anti‐cancer therapy
Essmann, F., & Schulze‐Osthoff, K. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01570.x · Cited by 77
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Valentine, J. M., Kumar, S., & Moumen, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-79 · Cited by 77
Rufino‐Palomares, E. E., Reyes‐Zurita, F. J., Garcı́a-Salguero, L., Mokhtari, K., Medina, P. P., Lupiáñez, J. A., & Peragón, J. (2013) · Journal of Proteomics · doi:10.1016/j.jprot.2013.02.031 · Cited by 75
Different mutation profiles associated to P53 accumulation in colorectal cancer
López, I., Oliveira, L. P., Tucci, P., Álvarez-Valín, F., Coudry, R. A., & Marín, M. (2012) · Gene · doi:10.1016/j.gene.2012.02.011 · Cited by 71
Wei, S., Wang, H., Lu, C., Malmut, S., Zhang, J., Ren, S., Yu, G., Wang, W., Tang, D. D., & Yan, C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.503755 · Cited by 57
MicroRNAs in colorectal cancer as markers and targets: Recent advances
Ye, J., & Cao, J. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i15.4288 · Cited by 50
Securinine induces p73‐dependent apoptosis preferentially in p53‐deficient colon cancer cells
Rana, S., Gupta, K., Gómez, J. A., Matsuyama, S., Chakrabarti, A., Agarwal, M. L., Agarwal, A., Agarwal, M. K., & Wald, D. N. (2010) · The FASEB Journal · doi:10.1096/fj.09-148999 · Cited by 50
Janoušková, H., Ray, A., Noulet, F., Lelong-Rebel, I. H., Choulier, L., Schaffner, F., Lehmann, M., Martin, S., Teisinger, J., & Dontenwill, M. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.03.018 · Cited by 49
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48
Meijer, A., Kruyt, F. A. E., van der Zee, A. G. J., Hollema, H., Le, P., ten Hoor, K. A., Groothuis, G. M. M., Quax, W. J., de Vries, E. G. E., & de Jong, S. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.636 · Cited by 46
Rigatti, M. J., Verma, R., Belinsky, G. S., Rosenberg, D. W., & Giardina, C. A. (2011) · Molecular Carcinogenesis · doi:10.1002/mc.20795 · Cited by 45
Cell Cycle Checkpoint Proteins and Cellular Response to Treatment by Anticancer Agents
Damia, G. L. M., & Broggini, M. (2004) · Cell Cycle · doi:10.4161/cc.3.1.631 · Cited by 45
Cordero‐Herrera, I., Martín, M. Á., Bravo, L., Goya, L., & Ramos, S. (2013) · Nutrition and Cancer · doi:10.1080/01635581.2013.795981 · Cited by 43
Hori, T., Kondo, T., Kanamori, M., Tabuchi, Y., Ogawa, R., Zhao, Q., Ahmed, K., Yasuda, T., Seki, S., Suzuki, K., et al. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.06.002 · Cited by 42
Reyes‐Zurita, F. J., Rufino‐Palomares, E. E., Medina, P. P., García-Salguero, E. L., Peragón, J., Cascante, M., & Lupiáñez, J. A. (2013) · Biochimie · doi:10.1016/j.biochi.2013.08.017 · Cited by 41
Marzo, D. D., Forte, I. M., Indovina, P., Gennaro, E. D., Rizzo, V., Giorgi, F. D., Mattioli, E., Iannuzzi, C. A., Budillon, A., Giordano, A., et al. (2013) · Cell Cycle · doi:10.4161/cc.27546 · Cited by 40
Epicatechin Gallate Impairs Colon Cancer Cell Metabolic Productivity
Sánchez‐Tena, S., Alcarraz‐Vizán, G., Marín, S., Torres, J. L., & Cascante, M. (2013) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf3052785 · Cited by 38
Lü, C., Wang, W., & El‐Deiry, W. S. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.12.7461 · Cited by 37
Sun, S. H., Zheng, M., Ding, K., Wang, S., & Sun, Y. (2008) · Cancer Biology & Therapy · doi:10.4161/cbt.7.6.5841 · Cited by 36
Over-Expression of Small Ubiquitin-Related Modifier-1 and Sumoylated p53 in Colon Cancer
Zhang, H., Kuai, X., Ji, Z., Li, Z., & Shi, R. (2013) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-013-9612-x · Cited by 30
Rieber, M., & Strasberg–Rieber, M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.09.003 · Cited by 30
Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth
Zhang, Y.-W., Zhang, Q., Zeng, S. X., Zhang, Y., Mayo, L. D., & Lu, H. (2012) · Cancer Biology & Therapy · doi:10.4161/cbt.20844 · Cited by 29
α-Lipoic acid prevents p53 degradation in colon cancer cells by blocking NF-κB induction of RPS6KA4
Yoo, T.-H., Lee, J., Chun, H.-S., & Chi, S.-G. (2013) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e32836181eb · Cited by 23
Nadler-Milbauer, M., Apter, L., Haupt, Y., Haupt, S., Barenholz, Y., Minko, T., & Rubinstein, A. (2011) · Journal of drug targeting · doi:10.3109/1061186x.2011.622401 · Cited by 12
MicroRNAs in Colorectal Cancer
Slabý, O., Svoboda, M., Michálek, J., & Vyzula, R. (2010) · Springer eBooks · doi:10.1007/978-94-007-0298-1_4 · Cited by 7
Cited by
Xiang, Y., Guo, Z., Zhu, P., Chen, J., & Huang, Y. (2019) · Cancer Medicine · doi:10.1002/cam4.2108 · Cited by 752
Zhong, X., He, X., Wang, Y., Hu, Z., Huang, H., Zhao, S., Wei, P., & Li, D. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01358-5 · Cited by 329
Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
Kumar, A., Gautam, V., Sandhu, A., Rawat, K., Sharma, A., & Saha, L. (2023) · World Journal of Gastrointestinal Surgery · doi:10.4240/wjgs.v15.i4.495 · Cited by 272
The molecular characteristics of colorectal cancer: Implications for diagnosis and therapy (Review)
Nguyen, H., & Duong, H. (2018) · Oncology Letters · doi:10.3892/ol.2018.8679 · Cited by 244
TRIM67 Activates p53 to Suppress Colorectal Cancer Initiation and Progression
Wang, S., Zhang, Y., Huang, J., Wong, C. C., Zhai, J., Li, C., Wei, G., Zhao, L., Wang, G., Wei, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3614 · Cited by 104
Metadata
- Authors
- Li, X.-L.
- Venue
- World Journal of Gastroenterology
- Publisher
- Baishideng Publishing Group Inc.
- Published
- 2015
- Volume
- 21
- Issue
- 1
- Pages
- 84
- ISSN
- 1007-9327 (ISSN-L)
- OpenAlex
- W2085653208
- Cited by
- 367
- References
- 83
- FWCI
- 10.40
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.